Pioneering ApproachesDelivering Innovation
We are committed to alleviating human suffering through the development of novel therapies.
Astex developed DACOGEN®, (decitabine) for INJECTION, a first generation hypomethylating agent. Dacogen is marketed by Otsuka in the USA where it is indicated for the treatment of myelodysplastic syndromes and by Janssen in over 40 countries in the rest of the world. Additionally, Dacogen® has been approved in the European Union to treat adults aged 65 or older with acute myeloid leukemia (AML), a type of cancer affecting the white blood cells. It is used in elderly patients with newly diagnosed AML who are not eligible for initial treatment with standard chemotherapy.
And, as an innovative leader in small-molecule drug discovery, we have a strong portfolio of proprietary and partnered drug products in clinical development.